


### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1. – 41. (Cancelled)

42. (Currently amended) A process for treating ~~and/or preventing~~ fibroses comprising administering a therapeutically effective amount of the pharmaceutical composition which comprises at least one biocompatible polymer of the following general formula (I):



wherein:

- A represents a monomer selected from the group consisting of a sugar or -(O-CH<sub>2</sub>-CH<sub>2</sub>-CO)-,

- X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: -R-COO-R', in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R' represents a hydrogen atom or a cation,

- Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: -R-O-SO<sub>3</sub>-R', -R-N-SO<sub>3</sub>-R', -R-SO<sub>3</sub>-R', in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R' represents a hydrogen atom or a cation,

- a represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 da,

- x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and

- y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.


Claims 43. – 60. (Cancelled)

61. (Previously presented) The process according to Claim 42, wherein the fibroses are fibroses of smooth muscle tissue.

62. (Previously presented) The process according to Claim 42, wherein the fibroses are fibroses of mesenchymal tissue.

63. (New) The process according to Claim 42, wherein the sugar is a glucose.

64. (New) A process for reducing fibroses comprising administering a therapeutically effective amount of the pharmaceutical composition which comprises at least one biocompatible polymer of the following general formula (I):



wherein :

- A represents a monomer selected from the group consisting of a sugar or  $-(O-CH_2-CH_2-CO)-$ ,
  - X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula :  $-R-COO-R'$ , in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R' represents a hydrogen atom or a cation,
  - Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group to one of the following formulas :  $-R-O-SO_3-R'$ ,  $-R-N-SO_3-R'$ ,  $-R-SO_3-R'$ , in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R' represents a hydrogen atom or a cation,
  - a represents the number of monomers A such that the mass of said polymers of formula (I) is greater than approximately 5,000 da,
  - x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and
- y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.